Baxter feeling the heat from Biogen's Eloctate
This article was originally published in Scrip
You may also be interested in...
The company believes there is room in the market for its more standard-acting hemophilia A products Kogenate and Kovaltry, as well as a long half-life product like Jivi.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.